Capabilities by Industry: Healthcare

Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia, Brazil and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.

In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.

Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals and biotechnology. 

Below we highlight a few of the transactions on which we have advised in this area:

Recent Transactions

15-Sep-20
$NA
United States flag
Target: 

Surgery Partners’ Anesthesia Services

United States flag
Acquiror: 
NorthStar Anesthesia

Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia   

12-Aug-20
Pending
$225 million
United States flag
Target: 

340B Link

United States flag
Acquiror: 
Omnicell

Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

10-Jun-20
Pending
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

10-Jun-20
$3.9 billion
Denmark flag
Target: 

Global collaboration agreement with Genmab A/S

United States flag
Acquiror: 
AbbVie, Inc

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

03-Jun-20
Pending
$NA
United States flag
Target: 

Cerner RevWorks

United States flag
Acquiror: 
R1 RCM

Advising Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services

23-Mar-20
Pending
$68 million
Target: 

Abacus Health Products, Inc.

Acquiror: 
Charlotte’s Web Holdings, Inc.

Advising Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products. 

18-Mar-20
$NA
Japan flag
Target: 

Centrifuge and processing equipment business of Koki Holdings Co., Ltd.

Germany flag
Acquiror: 
Eppendorf AG

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment 

02-Mar-20
$NA
United Kingdom flag
Target: 

Global rights (excluding North America) to ThermaCare (United Kingdom)

Italy flag
Acquiror: 
Angelini Pharma

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

20-Feb-20
Pending
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advising GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

15-Jan-20
$NA
United States flag
Target: 

OurHealth

United States flag
Acquiror: 
General Atlantic

Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health

19-Dec-18
$NA
United States flag
Target: 

Pfizer Inc. Consumer Health Business

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, U.S. subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a U.S. licensing agreement of its patented VivaGel BV® product with ITF Pharma, a U.S. subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

03-Dec-18
$4.0 billion
United Kingdom flag
Target: 

Assets owned by GlaxoSmithKline plc

Acquiror: 
Unilever plc / Hindustan Unilever Limited

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

30-Nov-18
$NA
United States flag
Target: 

Aisthesis

United States flag
Acquiror: 
NAPA Management Services Corporation

Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities

10-Sep-18
$100 million
Australia flag
Target: 

Montserrat Day Hospital Group

Australia flag
Acquiror: 
Primary Health Care

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

15-Aug-18
$3.9 billion
Canada flag
Target: 

Common shares and common share purchase warrants in Canopy Growth

United States flag
Acquiror: 
Constellation Brands

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

22-Jul-18
$NA
Brazil flag
Target: 

Cura Imagem e Diagnóstico Ltda.

Brazil flag
Acquiror: 
Vinci Partners

Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners

25-Jun-18
Pending
$NA
Brazil flag
Target: 

Cura Imagem e Diagnóstico Ltda.

Brazil flag
Acquiror: 
Vinci Partners

Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

30-Nov-17
$NA
Germany flag
Target: 

MorphoSys AG

China flag
Acquiror: 
I-Mab

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

18-Jul-17
$NA
Brazil flag
Target: 

Radiogroup Participações S.A.

Brazil flag
Acquiror: 
Grupo Oncoclínicas

Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas

11-May-17
$245 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia

10-Jan-17
$204 million
United States flag
Target: 

Derma Sciences, Inc.

United States flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
United States flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

United States flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

U.S. rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

U.S. rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

U.S. rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila

16-Jun-16
$40 million
Israel flag
Target: 

U.S. rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
Israel flag
Target: 

U.S. rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 8 generic drug products to Dr. Reddy’s Laboratories

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

01-Dec-15
$NA
United Kingdom flag
Target: 

Allied Healthcare

Germany flag
Acquiror: 
AURELIUS Investments

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

29-Oct-15
$275 million
United States flag
Target: 

Aesynt, Inc.

United States flag
Acquiror: 
Omnicell, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

06-Jul-15
$910 million
United States flag
Target: 

Altegra Health, Inc.

United States flag
Acquiror: 
Emdeon Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

08-Jun-15
$45 million
Canada flag
Target: 

Aralez Pharmaceuticals Inc.

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.

02-Jun-15
$NA
United Kingdom flag
Target: 

Portfolio of GlaxoSmithKline plc consumer and OTC brands

United States flag
Acquiror: 
Perrigo Company plc

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

11-Aug-14
$NA
United States flag
Target: 

MannKind Corporation

France flag
Acquiror: 
Sanofi

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

05-Feb-14
$NA
Sweden flag
Target: 

Unfors Raysafe AB

United States flag
Acquiror: 
Fluke Biomedical Corporation

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

18-Dec-13
$NA
United States flag
Target: 

Fidelis SeniorCare Inc. (Michigan Heath Plan)

United States flag
Acquiror: 
Centene Corporation

Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

20-Aug-12
$7.3 billion
United States flag
Target: 

Coventry Health Care Inc.

United States flag
Acquiror: 
Aetna

Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

26-Mar-12
$513 million
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

United States flag
Acquiror: 
Bausch + Lomb, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

07-Nov-11
$398 million
United States flag
Target: 

American Dental Partners, Inc.

United States flag
Acquiror: 
JLL Partners

Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm

30-Jun-11
$609 million
Japan flag
Target: 

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

United States flag
Acquiror: 
Royalty Pharma

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

13-May-11
$NA
Australia flag
Target: 

Bionomics Ltd

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

13-Dec-10
$256 million
United Kingdom flag
Target: 

Maxinutrition Group Holdings Limited

United Kingdom flag
Acquiror: 
GlaxoSmithKline Plc

Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity

07-Dec-10
$500 million
United States flag
Target: 

Medicity, Inc.

United States flag
Acquiror: 
Aetna Inc.

Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

21-Sep-10
$234 million
Israel flag
Target: 

Taro Pharmaceutical Industries

India flag
Acquiror: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

12-Jul-10
$NA
United States flag
Target: 

Breast Care Business of Ethicon-Endo Surgery

United States flag
Acquiror: 
Devicor Medical Products, Inc. (a GTCR portfolio company)

Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery

05-Apr-10
$225 million
United States flag
Target: 

Medegen, Inc

United States flag
Acquiror: 
CareFusion Corporation

Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company

23-Feb-10
$NA
United States flag
Target: 

Heartscape Technologies, Inc.

United States flag
Acquiror: 
Roper Industries, Inc.

Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

23-Jun-09
$155 million
United States flag
Target: 

Monogram Biosciences, Inc.

United States flag
Acquiror: 
Laboratory Corporation of America Holdings

Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

01-Oct-08
$53 million
Sweden flag
Target: 

Biotage (Biosystems division)

Netherlands flag
Acquiror: 
Qiagen NV

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

12-Jun-08
$6.7 billion
United States flag
Target: 

Applied Biosystems Group

United States flag
Acquiror: 
Invitrogen Corporation

Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a U.S. based provider of histopathology diagnostic equipment

25-Jan-07
$3.3 billion
United States flag
Target: 

Cardinal Health, Inc., Pharmaceutical Technologies and Services division

United States flag
Acquiror: 
The Blackstone Group

Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries

06-Nov-06
$4.2 billion
United States flag
Target: 

Kos Pharmaceuticals, Inc.

United States flag
Acquiror: 
Abbott Laboratories

Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

show 25 per page